Abstract: Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.

Abstract: Described herein are methods and assays for determining the presence or absence of certain markers useful in informing treatment of one or more subjects with one or more activin inhibitors. In certain aspects the one or more subjects can have cancer. In certain aspects the markers can include INHBA and ACVR2B. In certain aspects one or more subjects can be treated with an activin inhibitor.

Abstract: Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment by evaluating the subject's expression levels of specific biomarkers or angiogenic factors.